A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperparathyroidism Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Hyperparathyroidism, Primary Neoplasms Neoplasms by Site Parathyroid Diseases Parathyroid Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Treatment and study plan

AMG 073

Drug

Primary outcomes

Changes in serum calcium and PTH

Secondary outcomes

Safety and tolerability of cinacalcet

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Important dates

Study start: 2001
First posted: May 20, 2002
Registry last updated: May 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed